• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jerome P. Richie, MD


  • Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV.Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort.Prostate Cancer. 2014;2014:395078.
  • Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV.Maximum Tumor Diameter and the Risk of Prostate-Specific Antigen Recurrence After Radical Prostatectomy.Clin Genitourin Cancer. 2014 Mar 28.
  • Richie JP.Re: Testicular Cancer in Europe and the USA: Survival Still Rising among Older Patients.J Urol. 2014 May;191(5):1293.
  • Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV.The Effect of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer.Clin Genitourin Cancer. 2014 Mar 3.
  • Richie JP.Re: early development of the metabolic syndrome after chemotherapy for testicular cancer.J Urol. 2014 Apr;191(4):987.
  • Richie JP.Re: tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.J Urol. 2014 Mar;191(3):659.
  • Richie JP.Re: dynamic contrast-enhanced subtraction MRI for characterizing intratesticular mass lesions.J Urol. 2014 Feb;191(2):363.
  • Richie JP.Re: Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours.J Urol. 2013 Dec;190(6):2096.
  • Richie JP.Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.J Urol. 2013 Nov;190(5):1767-8.
  • Richie JP.Re: An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.J Urol. 2013 Oct;190(4):1251.
  • Richie JP.Re: A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life.J Urol. 2013 Sep;190(3):1045.
  • Richie JP.Re: genomic characterization of testis cancer: association of alterations with outcome of clinical stage 1 mixed germ cell nonseminomatous germ cell tumor of the testis.J Urol. 2013 Aug;190(2):537-8.
  • Richie JP.Re: barriers to the implementation of surveillance for stage I testicular seminoma.J Urol. 2013 Jun;189(6):2110-1.
  • Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M.Penile cancer.J Natl Compr Canc Netw. 2013 May 1;11(5):594-615.
  • Richie JP.Re: real-time tissue elastography for testicular lesion assessment.J Urol. 2013 May;189(5):1719-20.
  • Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M.Bladder cancer.J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75.
  • Richie JP.Re: clinical analysis of management of pediatric testicular germ cell tumors.J Urol. 2013 Apr;189(4):1532-3.
  • Richie JP.Re: second malignant neoplasms in testicular cancer survivors.J Urol. 2013 Mar;189(3):903.
  • Richie JP.Preclinical and clinical activity of sunitinib in patients with Cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group/German testicular cancer study group cooperative study.J Urol. 2013 Feb;189(2):533-4.
  • Richie JP.Re: Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.J Urol. 2013 Jan;189(1):128-9.
  • Richie JP.Re: incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.J Urol. 2012 Dec;188(6):2231-2.
  • Liong ML, Lim CR, Yang H, Chao S, Bong CW, Leong WS, Das PK, Loh CS, Lau BE, Yu CG, Ooi EJ, Nam RK, Allen PD, Steele GS, Wassmann K, Richie JP, Liew CC.Blood-based biomarkers of aggressive prostate cancer.PLoS ONE. 2012;7(9):e45802.
  • Richie JP.Re: sequelae of treatment in long-term survivors of testis cancer.J Urol. 2012 Nov;188(5):1771.
  • Richie JP.Re: The clinical features and management of testicular germ cell tumours in patients aged 60 years and older.J Urol. 2012 Oct;188(4):1184-5.
  • Richie JP.Re: Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.J Urol. 2012 Sep;188(3):815-6.
  • Richie JP.Re: Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour.J Urol. 2012 Aug;188(2):434-5.
  • Williams SB, Hirsch MS, Kantoff PW, Richie JP.Neuroepithelial Tumor Arising in a Testicular Teratoma With Retroperitoneal Metastasis.J Clin Oncol. 2012 Jun 11.
  • Richie JP.Re: First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.J Urol. 2012 Jul;188(1):115-6.
  • Williams SB, Chen MH, D'Amico AV, Weinberg AC, Kacker R, Hirsch MS, Richie JP, Hu JC.Radical Retropubic Prostatectomy and Robotic-assisted Laparoscopic Prostatectomy: Likelihood of Positive Surgical Margin(s).Urology. 2010 Nov;76(5):1097-101.
  • Williams SB, McDermott DW, Winston D, Bahnson E, Berry AM, Steele GS, Richie JP.Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data.BJU Int. 2010 Apr;105(7):918-21.
  • Williams SB, Kacker R, Steele GS, Richie JP.Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.Urol Oncol. 2010 Feb 27.
  • Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, Richie JP, de la Rosette JJ.A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer.Eur Urol. 2010 Feb;57(2):223-32. Review.
  • Williams SB, Steele GS, Richie JP.Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.J Urol. 2009 Dec;182(6):2716-20.
  • Rayala HJ, Richie JP.Radical prostatectomy reigns supreme.Oncology (Huntingt). 2009 Sep;23(10):863-7. Review.
  • Williams SB,McDermott DW,Dock W,Bahnson E,Berry AM,Steele GS,Richie JP.Retroperitoneal lymph node dissection in patients with high risk testicular cancer.J Urol. 2009 May;181(5):2097-101; discussion 2101-2.
  • Barrisford GW,Sartor O,Richie JP.Solitary adrenal metastatic lesion in a patient with a history of prostate cancer.Clin Genitourin Cancer. 2009 Jan;7(1):64-6.
  • Montie JE,Clark PE,Eisenberger MA,El-Galley R,Greenberg RE,Herr HW,Hudes GR,Kuban DA,Kuzel TM,Lange PH,Lele SM,Michalski J,Patterson A,Pohar KS,Richie JP,Sexton WJ,Shipley WU,Small EJ,Trump DL,Walther PJ,Wilson TG.Bladder cancer.J Natl Compr Canc Netw. 2009 Jan;7(1):8-39.
  • Prasad SM,Ferreria M,Berry AM,Lipsitz SR,Richie JP,Gawande AA,Hu JC.Surgical apgar outcome score: perioperative risk assessment for radical cystectomy.J Urol. 2009 Mar;181(3):1046-52; discussion 1052-3.
  • Silverman SG,Israel GM,Herts BR,Richie JP.Management of the incidental renal mass.Radiology. 2008 Oct;249(1):16-31. Review.
  • Richie JP.By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch?.Harv Health Lett. 2008 Jul;33(9):8.
  • Sommers BD,Beard CJ,D'Amico AV,Kaplan I,Richie JP,Zeckhauser RJ.Predictors of patient preferences and treatment choices for localized prostate cancer.Cancer. 2008 Oct 15;113(8):2058-67.
  • Prasad SM,Keating NL,Wang Q,Pashos CL,Lipsitz S,Richie JP,Hu JC.Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy.Urology. 2008 Sep;72(3):647-52; discussion 652-3.
  • Richie JP.Is full bilateral retroperitoneal lymph node dissection always necessary for post-chemotherapy residual tumor? Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH, Department of Urology and Oncology, Indiana University Medical Center, Indianapolis, IN.Urol Oncol. 2008 Mar-Apr;26(2):218-9.
  • Richie JP.High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R, Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN.Urol Oncol. 2008 Mar-Apr;26(2):218.
  • Richie JP.Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ, Department of Urology, University of California San Francisco, San Francisco, CA.Urol Oncol. 2008 Mar-Apr;26(2):219-20.
  • Richie JP.Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J. Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, NY.Urol Oncol. 2008 Mar-Apr;26(2):220.
  • Richie JP.Impact of diagnostic delay in testis cancer: Results of a large population-based study Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P, Human Fertility Research Group, Paule de Viguier Hospital, Toulouse University III, France; Urology and Andrology Department, Paule de Viguier Hospital, Toulouse, France.Urol Oncol. 2008 Mar-Apr;26(2):220-1.
  • Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC.New frontiers in nanotechnology for cancer treatment.Urol Oncol. 2008 Jan-Feb;26(1):74-85. Review.
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ.Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.Cancer. 2007 Nov 15;110(10):2210-7.
  • Richie J.By the way, doctor. I heard about a new test for prostate cancer that's better than the PSA test. Should I get this test?.Harv Health Lett. 2007 Aug;32(10):8.
  • Mukhopadhyay NK, Cinar B, Mukhopadhyay L, Lutchman M, Ferdinand AS, Kim J, Chung LW, Adam RM, Ray SK, Leiter AB, Richie JP, Liu BC, Freeman MR.The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer.Mol Endocrinol. 2007 Sep;21(9):2056-70.
  • Richie JP Jr, Komninou D, Albino AP.Induction of colon tumorigenesis by glutathione depletion in p53-knock-out mice.Int J Oncol. 2007 Jun;30(6):1539-43.
  • Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV.Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.Cancer. 2006 Dec 1;107(11):2597-603.
  • Mukhopadhyay NK, Ferdinand AS, Mukhopadhyay L, Cinar B, Lutchman M, Richie JP, Freeman MR, Liu BC.Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor.Exp Cell Res. 2006 Nov 15;312(19):3782-95.
  • Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV.Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.Cancer. 2006 Aug 1;107(3):514-20.
  • Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV.Radical prostatectomy for high-grade prostate cancer.Urology. 2006 Aug;68(2):367-70.
  • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.Development of an integrated prostate cancer research information system.Clin Genitourin Cancer. 2006 Jun;5(1):61-6.
  • Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R.Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20.
  • Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV.Evidence to support a continued stage migration and decrease in prostate cancer specific mortality.J Urol. 2006 Mar;175(3 Pt 1):907-12.
  • Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV.Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.Urology. 2005 Nov;66(5):1024-8.
  • McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, Richie JP, D'Amico AV.PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level.Urol Oncol. 2005 Sep-Oct;23(5):311-7.
  • Silverman SG, Tuncali K, vanSonnenberg E, Morrison PR, Shankar S, Ramaiya N, Richie JP.Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients.Radiology. 2005 Aug;236(2):716-24.
  • Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK.Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.Clin Cancer Res. 2005 Jul 15;11(14):5233-40.
  • Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV.Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.Urology. 2005 Mar;65(3):528-32.
  • Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'amico AV.Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.Urology. 2004 Feb;63(2):333-6.
  • D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP.Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.Urology. 2003 Dec;62(6):1063-7.
  • Coen JJ, Zietman AL, Thakral H, Shipley WU.Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.J Clin Oncol. 2002 Aug 1;20(15):3199-205.
  • D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.Cancer. 2002 Jul 15;95(2):281-6.
  • Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M, Wein A, Richie JP, D'Amico AV.Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy.Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):898-903.
  • Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.Gene expression correlates of clinical prostate cancer behavior.Cancer Cell. 2002 Mar;1(2):203-9.
  • Fielding JR, Hoyte LX, Okon SA, Schreyer A, Lee J, Zou KH, Warfield S, Richie JP, Loughlin KR, O'Leary MP, Doyle CJ, Kikinis R.Tumor detection by virtual cystoscopy with color mapping of bladder wall thickness.J Urol. 2002 Feb;167(2 Pt 1):559-62.
  • Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP.Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation.J Biol Chem. 2001 Apr 20;276(16):13442-51.
  • Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV.Optimizing patient selection for prostate monotherapy.Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):673-7.
  • Duque JL, Adam RM, Mullen JS, Lin J, Richie JP, Freeman MR.Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro.J Urol. 2001 Jan;165(1):284-8.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.Mol Urol. 2000 Fall;4(3):171-5;discussion 177.
  • D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP.Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score </= 7.Cancer. 2000 Oct 15;89(8):1810-7.
  • D'Amico AV, Weinstein M, Li X, Richie JP, Fujimoto J.Optical coherence tomography as a method for identifying benign and malignant microscopic structures in the prostate gland.Urology. 2000 May;55(5):783-7.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.J Clin Oncol. 2000 Mar;18(6):1164-72.
  • Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, Richie JP, Patel A, Walsh PC, Scardino PT, Lange PH, deKernion JB, Southwick PC, Loveland KG, Parson RE, Gasior GH.Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.Urology. 2000 Mar;55(3):372-6.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A.Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1227-33.
  • D'Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, Loughlin KR, Richie JP.Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate.Cancer. 1998 Nov 15;83(10):2172-80.
  • Duque JL, Loughlin KR, O'Leary MP, Kumar S, Richie JP.Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma.Urology. 1998 Oct;52(4):584-90.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A.Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy.J Clin Oncol. 1998 Sep;16(9):3094-100.
  • Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV.The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.Cancer. 1998 Aug 15;83(4):748-52.
  • Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW.Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study.J Clin Oncol. 1998 Jan;16(1):275-83.
  • Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI.Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer.J Nucl Med. 1996 Feb;37(2):315-20.